Elo Mutual Pension Insurance Co Trims Stock Position in Boston Scientific Co. (NYSE:BSX)

Elo Mutual Pension Insurance Co lowered its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 3.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 134,390 shares of the medical equipment provider's stock after selling 5,334 shares during the period. Elo Mutual Pension Insurance Co's holdings in Boston Scientific were worth $12,004,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. TFC Financial Management Inc. boosted its holdings in shares of Boston Scientific by 308.8% in the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 210 shares during the period. Dunhill Financial LLC boosted its stake in Boston Scientific by 86.4% during the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after buying an additional 152 shares during the period. Global Wealth Strategies & Associates increased its position in Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 250 shares during the last quarter. West Oak Capital LLC purchased a new stake in shares of Boston Scientific in the fourth quarter valued at $29,000. Finally, Valley National Advisers Inc. lifted its holdings in shares of Boston Scientific by 262.4% in the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 286 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Remove Ads

Boston Scientific Stock Down 1.5 %

Shares of BSX traded down $1.51 during trading hours on Friday, hitting $99.29. The company had a trading volume of 7,402,670 shares, compared to its average volume of 6,051,507. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $146.86 billion, a PE ratio of 79.43, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a one year low of $66.80 and a one year high of $107.17. The company's fifty day moving average price is $102.16 and its two-hundred day moving average price is $93.04.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, equities analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the topic of a number of recent analyst reports. StockNews.com lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th. JPMorgan Chase & Co. increased their price target on Boston Scientific from $100.00 to $110.00 and gave the stock an "overweight" rating in a report on Monday, December 16th. Truist Financial boosted their price objective on Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, December 18th. Piper Sandler upped their price objective on Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Finally, Argus set a $130.00 target price on Boston Scientific in a research report on Tuesday, February 18th. Two equities research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $108.91.

Insiders Place Their Bets

In other news, EVP John Bradley Sorenson sold 4,119 shares of the business's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total transaction of $370,792.38. Following the sale, the executive vice president now owns 35,319 shares in the company, valued at approximately $3,179,416.38. The trade was a 10.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the completion of the transaction, the executive vice president now directly owns 28,454 shares of the company's stock, valued at $2,966,329.50. The trade was a 14.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 137,302 shares of company stock valued at $14,319,269. 0.50% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.